Genmab CEO raises ambitions: "Innovators are the future leaders"

On the company's capital markets day 2018, Genmab launched a new technology platform and announced the establishment of a commercial organization, more clinical projects and an increased focus on partnerships and custom-made medicine. However, the new initiatives come with a price and while the CEO is excited, the investors seem worried.

Foto: /Ritzau/Mik Eskestad/

"Biotech companies are not necessarily the weak part that just want money from the medical groups. That time is over and I believe the innovators will be the future leaders."

This was how Jan van de Winkel, CEO in Genmab, responded to the analysts when asked about his expectations regarding new partnership deals with firms wanting to utilize Genmab's technologies DuoBody, Hexabody and the latest addition, HexElect.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch


Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier